spite
advanc
nutrit
genet
hous
therapeut
diseas
respiratori
reproduct
enter
tract
domest
anim
poultri
continu
major
caus
morbid
mortal
econom
loss
billion
dollar
year
whiteley
et
al
although
vaccin
develop
licens
prevent
mani
diseas
summar
tabl
need
improv
vaccin
efficaci
reason
low
vaccin
efficaci
includ
inappropri
antigen
vaccin
prepar
eg
vitro
express
antigen
instead
vivo
express
antigen
inappropri
immun
respons
eg
system
instead
mucos
instead
inappropri
use
otherwis
efficaci
vaccin
eg
vaccin
onset
diseas
tizard
major
current
poultri
vaccin
attenu
agent
deliv
oral
nasal
mucos
rout
reason
eas
administr
economi
protect
efficaci
rel
recent
howev
vaccin
domest
mammal
deliv
mucos
rout
manag
practic
mammal
differ
poultri
mass
vaccin
techniqu
mucos
deliveri
pursu
zealous
recent
howev
number
attenu
live
vaccin
nasal
administr
develop
respiratori
tract
infect
especi
hors
pet
use
tradit
methodolog
improv
protect
efficaci
rapid
onset
immun
comparison
kill
vaccin
product
led
widespread
accept
attenu
live
vaccin
enter
diseas
also
market
mani
case
efficaci
disappoint
better
strategi
induct
immun
gastrointestin
tract
need
contrast
effect
parenter
vaccin
common
diseas
reproduct
tract
veterinari
speci
avail
year
littl
motiv
develop
mucos
vaccin
mani
diseas
respiratori
gastrointestin
tract
devast
neonat
period
diseas
activ
immun
may
provid
protect
natur
exposur
pathogen
matern
vaccin
enhanc
passiv
immun
wide
use
veterinari
medicin
especi
control
enter
diseas
sever
practic
difficulti
aris
howev
diseas
parvoviru
enter
puppi
smooth
transit
must
made
protect
passiv
matern
antibodi
protect
activ
immun
without
permit
window
diseas
suscept
occur
transit
difficult
achiev
induct
activ
immun
commonli
inhibit
matern
antibodi
variou
strategi
use
address
problem
improv
adjuv
antigen
deliveri
system
would
improv
reliabl
neonat
immun
although
progress
made
diseas
prevent
veterinari
speci
everchang
manag
practic
eg
earlier
wean
piglet
larger
dairi
oper
appear
gener
new
pattern
diseas
requir
new
control
strategi
emerg
new
pathogen
eg
porcin
reproduct
respiratori
syndrom
viru
prrsv
porcin
also
present
new
challeng
vaccin
research
older
challeng
met
chapter
focu
mucos
veterinari
vaccin
vaccin
concept
relat
select
pathogen
associ
econom
import
respiratori
reproduct
enter
diseas
emphasi
livestock
speci
intent
highlight
progress
review
exist
futur
vaccin
strategi
acknowledg
uniqu
contribut
research
understand
mucos
vaccin
immunolog
respiratori
tract
infect
major
caus
morbid
mortal
among
farm
anim
poultri
pet
tabl
mani
case
diseas
condit
intensifi
current
manag
practic
mix
recent
wean
stress
beef
calv
multipl
sourc
auction
barn
certain
diseas
condit
atroph
rhiniti
pig
result
interplay
sever
pathogen
multipl
agent
must
repres
vaccin
respiratori
pathogen
mycoplasma
hyopneumonia
young
pig
caus
new
pattern
diseas
manag
practic
chang
eg
wean
earlier
age
requir
chang
vaccin
strategi
pathogen
prrsv
recent
emerg
improv
vaccin
await
advanc
understand
agent
diseas
pathogenesi
discuss
respiratori
vaccin
even
major
pathogen
veterinari
speci
beyond
scope
present
review
section
therefor
focus
select
pathogen
cattl
hors
illustr
gener
principl
respiratori
tract
diseas
major
problem
beef
veal
dairi
produc
decad
perspect
econom
anim
welfar
consider
efficaci
practic
mean
reduc
burden
diseas
long
overdu
attent
focus
pneumon
pasteurellosi
commonli
term
ship
fever
recent
wean
beef
calv
soon
entri
feedlot
econom
loss
north
american
feedlot
industri
alon
estim
nearli
billion
per
year
whiteley
et
al
includ
loss
due
enzoot
pneumonia
veal
dairi
beef
calv
wean
bacteria
virus
implic
diseas
process
vaccin
market
year
mosier
et
al
summar
agent
associ
respiratori
diseas
cattl
vaccin
prepar
market
control
tabl
mannheimia
haemolytica
discuss
detail
exampl
past
current
futur
vaccin
approach
haemolytica
classifi
recent
pasteurella
haemolytica
angen
et
al
gramneg
facult
anaerob
bacterium
experiment
studi
caus
fibrin
pneumonia
compar
seen
cattl
die
pneumon
pasteurellosi
friend
et
al
shoo
consid
import
bacteri
pathogen
bovin
pneumonia
mosier
first
decad
vaccin
histori
review
mosier
et
al
singl
agent
bacterium
induc
pneumonia
experiment
studi
field
case
pneumonia
involv
predispos
factor
stress
sudden
shift
weather
condit
chang
feed
wean
commingl
cattl
interact
viral
pathogen
review
yate
hodgin
et
al
effect
vaccin
strategi
respiratori
diseas
feedlot
cattl
therefor
need
induc
immun
multipl
pathogen
haemolytica
cultur
intermitt
nasopharynx
healthi
cattl
consid
part
normal
flora
babiuk
acr
frank
illdefin
condit
stress
haemolytica
serotyp
popul
increas
rapidli
nasopharynx
frank
smith
invas
lower
respiratori
tract
facilit
mani
case
viral
effect
clearanc
mechan
tracheal
bronchial
mucosa
lead
vascular
damag
exud
fibrin
necrosi
lung
parenchym
tissu
lesion
review
rehmtulla
thomson
morbid
rate
mortal
rate
common
among
wean
calv
arriv
feedlot
kelli
janzen
antibiot
use
extens
treatment
prevent
mechor
et
al
hoar
et
al
earliest
vaccin
ship
fever
bacterin
doubt
efficaci
miller
et
al
caus
detriment
effect
farley
friend
et
al
identif
character
heatlabil
exotoxin
leukotoxin
cytolyt
rumin
leukocyt
produc
haemolytica
logarithm
growth
shewen
wilki
initi
intens
search
protect
antigen
haemolytica
continu
today
antigen
suggest
play
role
diseas
pathogenesi
potenti
valu
vaccin
formul
includ
capsular
polysaccharid
haemolytica
brogden
et
al
sialoglycoproteas
abdullah
et
al
lee
et
al
neuroaminidas
strau
purdi
outer
membran
protein
gatewood
et
al
fimbria
morck
et
al
morck
et
al
ironregul
protein
morck
et
al
potter
et
al
haemolytica
vaccin
avail
commerci
consist
cultur
supernat
cell
extract
without
leukotoxin
licens
use
intramuscular
subcutan
rout
signific
protect
experiment
challeng
studi
report
number
product
conlon
et
al
conlon
et
al
confer
fulton
investig
vaccin
efficaci
conduct
almost
exclus
rumin
leukotoxin
best
document
virul
factor
toxic
rumin
leukocyt
kaehler
et
al
shewen
wilki
efficaci
field
trial
consider
lower
control
experi
suboptim
time
vaccin
variat
exposur
pathogen
haemolytica
variat
immun
haemolytica
nonvaccin
control
calv
thorlakson
et
al
gener
proport
igg
iga
respiratori
tract
secret
increas
upper
respiratori
tract
lower
respiratori
tract
unclear
howev
proport
igg
detect
bovin
lung
result
local
secret
much
serum
deriv
butler
protect
mediat
parenter
vaccin
nonrepl
vaccin
suggest
serum
antibodi
least
limit
access
lung
compart
number
attempt
made
develop
live
haemolytica
vaccin
parenter
intraderm
intramuscular
administr
efficaci
studi
yield
variabl
result
smith
et
al
purdi
et
al
mosier
et
al
approach
limit
use
feedlot
calv
use
antibiot
prevent
adequ
replic
live
vaccin
major
challeng
develop
effect
vaccin
haemolytica
adapt
vaccin
exist
manag
practic
adapt
manag
practic
feasibl
vaccin
limit
opportun
vaccin
beef
calv
rais
openrang
land
wean
convent
twodos
vaccin
primari
vaccin
week
wean
labor
intens
increas
stress
calv
delay
vaccin
singl
dose
vaccin
time
feedlot
arriv
induc
anamnest
respons
calv
prime
natur
exposur
conlon
et
al
allow
suffici
time
highli
suscept
calv
respond
immunolog
one
approach
merit
vaccin
calv
month
age
handl
brand
harland
et
al
follow
booster
dose
wean
month
age
oral
vaccin
recent
studi
shown
transgen
clover
express
truncat
form
leukotoxin
haemolytica
potenti
oral
vaccin
lee
et
al
oral
administr
dri
transgen
plant
materi
would
lowlabor
lowstress
method
vaccin
doubt
whether
plantexpress
antigen
surviv
passag
rumen
first
stomach
rumin
speci
author
hypothes
repeat
exposur
tonsil
antigen
rumin
induc
mucos
immun
respons
immunogen
trial
recombin
plant
antigen
calv
report
other
report
live
genet
modifi
haemolytica
administ
recent
wean
calv
top
dress
pellet
feed
brigg
tatum
hypothes
vaccin
strain
haemolytica
could
colon
nasopharynx
without
caus
pneumon
diseas
induc
mucos
immun
respons
mortal
highrisk
feedlot
calv
reduc
signific
increas
iga
antibodi
note
nasal
secret
day
postvaccin
result
promis
continu
studi
need
confirm
lack
virul
vari
feedlot
condit
environment
consider
potenti
contamin
runoff
water
feedlot
vaccin
thousand
cattl
could
also
block
licens
anoth
approach
involv
microencapsul
nonrepl
antigen
oral
immun
rumin
bowersock
et
al
anatomi
rumin
digest
tract
prolong
passag
time
materi
linger
rumen
complic
vaccin
oral
rout
incorpor
microencapsul
antigen
macroparticl
mm
diamet
allow
antigen
bypass
rumen
bowersock
et
al
pass
promptli
reticulum
second
stomach
oral
vaccin
contain
microencapsul
antigen
haemolytica
shown
induc
partial
protect
bowersock
et
al
nasal
vaccin
preliminari
work
rebelatto
et
al
indic
vaccin
nasal
rout
use
algin
microencapsul
antigen
may
use
cattl
nasal
oral
vaccin
led
high
level
igg
antibodi
serum
nasal
secret
dnabas
vaccin
strategi
immun
larg
anim
plasmid
vaccin
proven
difficult
mice
braun
et
al
babiuk
et
al
dose
administ
cattl
attempt
optim
immun
respons
although
longliv
immun
respons
induc
braun
et
al
antibodi
respons
develop
slowli
comparison
induc
proteinbas
vaccin
revaccin
may
necessari
detect
respons
braun
et
al
attribut
discourag
use
plasmid
dna
technolog
vaccin
haemolytica
sinc
frequenc
vaccin
labor
cost
key
issu
advanc
plasmid
design
deliveri
babiuk
et
al
combin
plasmid
vaccin
vaccin
approach
may
make
dna
vaccin
feasibl
use
cattl
unmethyl
cpg
oligodeoxynucleotid
investig
potenti
adjuv
veterinari
vaccin
rankin
et
al
may
find
role
convent
proteinbas
vaccin
plasmid
dna
vaccin
respiratori
tract
diseas
affect
virtual
everi
aspect
equin
husbandri
includ
work
pleasur
race
hors
consider
effort
expend
prevent
epizoot
respiratori
diseas
stabl
fair
show
race
track
summar
major
respiratori
pathogen
hors
vaccin
prepar
market
control
tabl
equin
influenza
viru
discuss
detail
exampl
past
current
futur
vaccin
approach
equin
influenza
viru
caus
epizoot
upper
lower
respiratori
tract
diseas
almost
worldwid
infect
occur
hors
age
epidem
often
involv
younger
anim
van
maanen
cullinan
clinic
sign
includ
high
fever
persist
dri
cough
nasal
discharg
anorexia
depress
ardan
secondari
bacteri
pneumonia
may
complic
clinic
pictur
timoney
equin
influenza
virus
classifi
type
influenza
antigen
differ
hemagglutinin
h
neuraminidas
n
glycoprotein
defin
two
recogn
subtyp
wilson
subtyp
associ
outbreak
equin
influenza
sinc
timoney
van
maanen
cullinan
two
lineag
american
european
identifi
yate
mumford
multipl
viru
strain
includ
vaccin
sinc
protect
heterolog
strain
incomplet
yate
mumford
antigen
drift
suffici
requir
regular
reapprais
strain
includ
vaccin
mumford
wood
natur
infect
induc
iga
antibodi
nasal
secret
igga
iggb
antibodi
serum
nelson
et
al
circul
cytotox
lymphocyt
protect
reinfect
persist
least
year
hannant
et
al
vaccin
inactiv
viru
vaccin
induc
serum
igg
antibodi
without
detect
iga
nasal
secret
nelson
et
al
without
cytotox
cell
activ
van
maanen
cullinan
two
three
dose
vaccin
typic
administ
primari
seri
booster
dose
administ
least
year
thereaft
frequent
vaccin
advis
hors
high
risk
infect
wilson
protect
typic
incomplet
limit
durat
morley
et
al
improv
adjuv
enhanc
level
durat
antibodi
respons
inactiv
viru
vaccin
mumford
et
al
van
maanen
cullinan
suppress
effect
matern
antibodi
respons
inactiv
vaccin
led
recommend
vaccin
foal
month
age
van
oirschot
et
al
van
maanen
cullinan
subunit
equin
influenza
vaccin
base
iscom
adjuv
technolog
licens
market
europ
sinc
newmark
antibodi
respons
iscombas
vaccin
typic
higher
titer
persist
stimul
convent
inactiv
vaccin
mumford
et
al
brugmann
et
al
protect
demonstr
experiment
challeng
month
threedos
vaccin
seri
mumford
et
al
protect
may
due
part
abil
iscomadjuv
vaccin
induc
cytotox
lymphocyt
ctl
morein
et
al
although
iscombas
vaccin
induc
iga
antibodi
respons
follow
nasal
administr
hu
et
al
commerci
influenza
iscom
vaccin
administ
parenter
nasal
vaccin
nasal
administr
inactiv
equin
influenza
cholera
toxin
b
subunit
report
induc
mucos
iga
antibodi
protect
experiment
challeng
hannant
et
al
recent
coldadapt
temperaturesensit
live
vaccin
nasal
administr
commerci
protect
experiment
challeng
demonstr
month
singl
vaccin
notabl
improv
efficaci
practic
convent
kill
vaccin
plasmid
dna
vaccin
experiment
plasmid
vaccin
encod
hemagglutinin
gene
equin
influenza
examin
hors
three
dose
plasmid
administ
skin
mucos
site
tongu
conjunctiva
third
eyelid
induc
protect
clinic
diseas
partial
protect
viral
shed
protect
clinic
diseas
reduc
plasmid
administ
skin
lunn
et
al
canarypox
alvac
strain
attenu
vaccinia
viru
nyvac
strain
use
vaccin
vector
express
hemagglutinin
subtyp
equin
influenza
viru
intramuscular
vaccin
induc
serum
antibodi
partial
protect
achiev
follow
natur
exposur
influenza
viru
taylor
et
al
respiratori
pathogen
eg
hyopneumonia
pig
critic
antigen
associ
protect
immun
respons
identifi
pathogen
eg
prrsv
also
need
identifi
appropri
immun
respons
type
need
protect
complex
diseas
condit
eg
pneumon
pasteurellosi
cattl
continu
uncertainti
whether
relev
contribut
pathogen
identifi
although
mani
parenter
vaccin
efficaci
reduc
lower
respiratori
tract
diseas
need
investig
whether
induct
mucos
immun
upper
airway
combin
system
immun
reduc
infect
rate
transmiss
pathogen
econom
loss
final
need
devis
implement
chang
manag
procedur
reduc
diseas
exposur
nonimmunolog
method
optim
immun
intervent
improv
time
vaccin
vaccin
prevent
reproduct
tract
diseas
receiv
much
emphasi
veterinari
medicin
especi
true
foodproduc
anim
reproduct
failur
econom
problem
although
vaccin
prevent
reproduct
interest
abandon
pet
deer
area
overpopul
section
deal
vaccin
design
prevent
infecti
diseas
reproduct
mucosa
outlin
summar
pathogen
associ
reproduct
tract
diseas
veterinari
speci
vaccin
prepar
market
control
tabl
infect
caus
advers
pregnanc
outcom
classifi
rout
infect
hematogen
ascend
sever
hematogen
infect
predilect
gravid
uteru
result
earli
late
abort
includ
leptospirosi
chlamydi
infect
brucellosi
sever
anim
speci
haemophilu
somnu
infect
cattl
sheep
neospora
caninum
infect
cattl
although
vaccin
avail
leptospirosi
hemophilosi
vaccin
brucellosi
avail
sinc
prototyp
sever
brucella
speci
caus
abort
epididymitisorch
primari
host
b
abortu
cattl
b
sui
swine
b
melitensi
goat
b
ovi
sheep
b
cani
dog
b
marinum
b
delphini
marin
mammal
infect
may
acquir
via
gut
mucosa
conjunctivaupp
respiratori
mucosa
infect
local
reticuloendotheli
system
endometriumplacenta
system
spread
thu
system
vaccin
effect
modifi
live
b
abortu
vaccin
along
test
slaughter
erad
program
success
control
bovin
brucellosi
north
america
modifi
live
vaccin
b
abortu
strain
effect
stimul
cellmedi
immun
cmi
critic
protect
facult
intracellular
pathogen
strain
larg
replac
new
attenu
strain
stimul
antibodi
respons
known
interfer
diagnost
assay
consider
inform
mechan
immun
brucellosi
sinc
focu
volum
mucos
immun
said
hematogen
infect
genit
tract
ascend
local
infect
reproduct
tract
usual
transmit
sexual
two
best
exampl
vaccin
sexual
transmit
infect
anim
campylobact
fetu
subsp
venereali
formerli
vibrio
fetu
subsp
venereali
tritrichomona
foetu
hostspecif
bovin
sexual
transmit
diseas
std
pathogen
infect
reproduct
mucosa
extracellular
pathogen
invad
mucosa
reproduct
tract
may
found
placenta
fetu
local
natur
infect
transmiss
limit
coitu
suggest
mucos
immun
must
import
vaccin
avail
c
fetu
subsp
venereali
sever
decad
use
control
diseas
develop
countri
vaccin
describ
first
vibriosi
campylobacteriosi
chronic
bacteri
genit
infect
overt
clinic
sign
reproduct
failur
corbeil
et
al
month
infect
uteru
clear
first
follow
vagina
convalesc
immun
partial
protect
limit
time
antibodi
effect
protect
extracellular
pathogen
demonstr
system
passiv
immun
berg
et
al
antibodi
respons
infect
primarili
iga
vagina
igg
uteru
corbeil
et
al
system
immun
whole
cell
vaccin
result
antibodi
respons
surfac
antigen
serum
uterin
vagin
secret
corbeil
et
al
respons
prevent
infect
rapidli
clear
infect
cow
corbeil
winter
vaccin
use
prophylact
therapeut
immun
efficaci
even
though
surfac
antigen
variat
occur
face
local
immun
respons
corbeil
winter
presum
immun
clearanc
occur
dynam
interact
protect
evas
shift
favor
host
appear
occur
earlier
respons
primarili
igg
iga
predomin
corbeil
et
al
may
relat
abil
igg
antibodi
mediat
opson
intracellular
kill
bacterium
abil
iga
antibodi
lack
corbeil
winter
although
work
done
mani
year
ago
set
preced
system
immun
prophylaxi
therapi
reproduct
mucos
infect
trichomoniasi
similar
chronic
genit
mucos
infect
cattl
caus
protozoan
foetu
result
pregnanc
loss
vaginali
caus
human
std
also
associ
advers
pregnanc
outcom
thu
bovin
trichomoniasi
serv
model
immun
prevent
human
reproduct
mucos
infect
econom
signific
bovin
trichomoniasi
chemotherapi
use
owe
toxic
investig
focus
immunoprophylaxi
therapi
like
c
fetu
subsp
venereali
foetu
colon
vagin
uterin
preputi
surfac
month
fact
matur
bull
often
infect
life
wherea
young
bull
may
clear
infect
time
probabl
relat
innat
immun
trichomonad
anaerob
parasit
found
deep
uterin
gland
epitheli
crypt
peni
prepuc
rhyan
et
al
oxygen
tension
probabl
lowest
order
elucid
protect
acquir
immun
respons
monoclon
antibodi
mab
put
protect
function
chosen
immunoaffin
purif
highli
glycosyl
surfac
antigen
analysi
mani
isol
foetu
indic
two
mab
recogn
differ
epitop
antigen
conserv
isol
test
glycosyl
surfac
antigen
later
shown
lipophosphoglycan
lpg
protein
complex
system
immun
immunoaffinitypurifi
surfac
antigen
follow
vagin
challeng
foetu
result
statist
significantli
earlier
clearanc
parasit
vaccin
anim
control
even
import
clearanc
immun
anim
often
occur
week
infect
mucos
convalesc
immun
clear
control
much
later
other
show
signific
inflamm
accompani
reproduct
failur
occur
week
infect
vaccin
protect
fetal
loss
parsonsen
et
al
analysi
antibodi
respons
demonstr
predominantli
respons
serum
iga
plu
antibodi
secret
rais
sever
question
first
system
respons
skew
toward
respons
cattl
respons
question
investig
second
protect
igg
iga
antibodi
ig
class
enrich
enhanc
protect
address
latter
question
preliminari
studi
done
mice
determin
best
rout
adjuv
enrich
igg
iga
genit
secret
subcutan
prime
immunoaffin
purifi
surfac
antigen
call
antigen
quil
adjuv
subcutan
boost
whole
cell
enrich
igg
antibodi
wherea
subcutan
prime
vagin
boost
greatli
enrich
iga
antibodi
genit
secret
cattl
immun
two
method
challeng
vagin
foetu
predominantli
iga
predominantli
antibodi
genit
secret
equal
protect
later
studi
similar
nasal
immun
show
stimul
common
mucos
immun
system
yield
result
similar
vagin
immun
rais
question
induct
site
local
immun
respons
genit
tract
other
suggest
genit
tract
induct
site
cell
mucosaassoci
lymphoreticular
tissu
malt
present
true
cattl
well
mice
human
howev
even
though
control
cow
histolog
demonstr
malt
uteru
vagina
cow
experiment
infect
foetu
similar
lymphoid
nodul
follicl
modifi
epithelium
detect
preputi
penial
surfac
bull
infect
foetu
rhyan
et
al
immunostain
parallel
section
mab
antigen
indic
uptak
antigen
epitheli
cell
larg
macrophag
dendrit
type
cell
basement
membran
near
lymphoid
follicl
rhyan
et
al
similar
antigen
uptak
detect
infect
femal
uterin
vagin
mucosa
unpublish
data
rhyan
jc
bondur
rh
corbeil
lb
thu
even
though
parasit
noninvas
releas
antigen
appear
taken
epitheli
cell
rat
uterin
epitheli
cell
present
antigen
th
cell
wira
rossol
also
macrophagedendrit
type
cell
posit
antigen
antigenpres
cell
apc
detect
iga
antibodi
antigen
genit
secret
infect
anim
rhyan
et
al
cow
histolog
demonstr
follicl
put
apc
suggest
induct
site
genit
tract
form
respons
antigen
like
c
fetu
subsp
venereali
foetu
mechan
evas
immun
respons
includ
coat
surfac
ig
nonspecif
epitop
variat
ikeda
et
al
cleavag
complement
compon
extracellular
cystein
proteinas
talbot
et
al
kania
et
al
howev
c
fetu
clear
dynam
interact
host
parasit
made
favor
host
system
mucos
immun
use
whole
cell
vaccin
prevent
foetu
cow
demonstr
clinic
trial
kvasnicka
et
al
earlier
clark
et
al
demonstr
efficaci
immun
bull
whole
foetu
cell
crude
membran
glycoprotein
probabl
contain
antigen
firstgener
whole
cell
vaccin
commerci
avail
prevent
trichomoniasi
cow
studi
c
fetu
subsp
venereali
foetu
show
std
prevent
even
cure
system
vaccin
male
femal
least
one
std
igg
iga
antigen
specif
equal
protect
mucos
surfac
induct
site
form
mucosa
infect
male
femal
genit
tract
even
noninvas
pathogen
strong
appropri
immun
respons
clear
microbi
infect
genit
tract
even
microb
multipl
immun
evas
mechan
protect
two
std
demonstr
natur
outbr
host
cattl
thu
advantag
murin
model
std
vaccin
latter
human
pathogen
usual
inocul
abnorm
murin
host
diseas
mimic
human
infect
furthermor
although
inbr
mice
provid
homogen
experiment
model
repres
variat
immun
respons
seen
human
popul
work
bovin
vibriosi
trichomoniasi
demonstr
protect
field
condit
two
std
caus
advers
pregnanc
outcom
outbr
host
encourag
preced
control
human
std
relat
advers
pregnanc
outcom
futur
need
includ
identif
protect
antigen
std
antibodymedi
protect
genit
mucosa
sever
question
yet
address
allud
earlier
clear
igg
cross
mucos
epithelium
secret
sinc
lack
secretori
compon
polymer
ig
receptormedi
type
transportto
knowledg
role
ige
genit
tract
larg
unstudi
last
manipul
genit
immun
respons
enhanc
respons
unexplor
research
area
import
protect
intracellular
extracellular
pathogen
use
dna
recombin
vaccin
includ
gene
appropri
cytokin
may
approach
meet
need
enter
diseas
major
caus
mortal
morbid
anim
agent
caus
diarrhea
anim
includ
virus
eg
adenovirus
pestivirus
calicivirus
coronavirus
parvovirus
rotavirus
torovirus
bacteria
eg
campylobact
spp
clostridium
spp
diarrheagen
escherichia
coli
salmonella
spp
yersinia
spp
parasit
eg
coccidia
spp
cryptosporidium
parvum
infect
occur
commonli
suckl
anim
poultri
less
week
age
may
also
common
postwean
suscept
seroneg
stress
adult
anim
saif
jackwood
summar
veterinari
vaccin
market
prevent
control
diseas
caus
mucos
pathogen
tabl
attach
adhes
colon
replic
invas
enter
pathogen
larg
local
gastrointestin
tract
immun
effector
intestin
surfac
eg
secretori
iga
antibodi
cytokin
cytotox
nk
cell
play
critic
role
protect
immun
enter
pathogen
differ
characterist
relat
intestin
tropism
replic
requir
differ
vaccin
strategi
enter
virus
predilect
replic
distinct
vertic
longitudin
region
small
intestin
larg
intestin
saif
caus
diarrhea
variabl
sever
via
mechan
differ
enter
bacteria
caus
secretori
diarrhea
mediat
enterotoxin
bertsching
enter
virus
produc
cytolyt
infect
enterocyt
lead
vari
degre
villu
loss
fusion
result
reduc
absorpt
capac
small
intestin
malabsorpt
maldigest
diarrhea
rotaviru
nonstructur
protein
reportedli
function
viral
enterotoxin
play
role
pathogenesi
rotaviru
diarrhea
accord
result
studi
mice
est
et
al
role
rotaviru
diarrhea
speci
confirm
enter
nervou
system
recogn
critic
compon
regul
fluid
secret
normal
gut
key
element
pathophysiolog
rotaviru
diarrhea
mice
lundgren
et
al
neural
reflex
pathway
increas
fluid
secret
enterocyt
respons
infect
rotaviru
enter
pathogen
review
jone
blikslag
enteropathogen
virus
divid
three
type
accord
prefer
site
replic
intestin
review
saif
although
virus
hepat
virus
picornavirus
includ
human
poliovirus
enterovirus
shed
fece
replic
enterocyt
caus
system
gastrointestin
infect
polioviru
vaccin
oral
parenter
often
cite
quintessenti
enter
viral
vaccin
induc
system
neutral
antibodi
prevent
extraintestin
viral
spread
paralyt
polioth
applic
polioviru
model
immun
local
enter
infect
thu
limit
type
virus
infect
small
intestin
villou
enterocyt
via
lumin
surfac
includ
canin
coronaviru
porcin
transmiss
gastroenter
coronaviru
tgev
rotaviru
astroviru
caliciviru
tgev
infect
destroy
absorpt
enterocyt
entir
villi
throughout
small
intestin
caus
pronounc
villou
atrophi
often
fatal
diarrhea
rotaviru
astroviru
infect
restrict
within
villi
occur
mainli
mid
distal
small
intestin
caus
less
sever
villou
atrophi
diarrhea
enter
calicivirus
infect
villou
enterocyt
proxim
small
intestin
induc
moder
villou
atrophi
diarrhea
type
ii
virus
adenovirus
bovin
coronavirus
torovirus
porcin
epidem
diarrhea
coronaviru
pedv
infect
villou
crypt
enterocyt
distal
small
intestin
larg
intestin
induc
moder
sever
villou
atrophi
crypt
aplasia
diarrheatyp
iii
virus
enter
parvovirus
infect
crypt
enterocyt
basolater
caus
crypt
aplasia
sever
villou
atrophi
mucos
collaps
sever
hemorrhag
often
fatal
diarrhea
saif
thu
parvoviru
infect
prevent
system
immun
wherea
prevent
local
enter
viru
infect
type
ii
reli
larg
intestin
immun
enteropathogen
bacteria
determin
virul
factor
includ
adhes
factor
fimbria
pili
enterotoxin
therefor
bacteri
vaccin
gener
need
prevent
attach
toxin
action
within
intestin
bertsching
follow
section
review
vaccin
strategi
type
ii
iii
enter
infect
tgev
rotaviru
vaccin
pig
review
illustr
find
concern
domest
outbr
anim
instead
inbr
laboratori
rodent
model
prevent
local
intestin
infect
requir
presenc
suffici
level
antibodi
site
pathogen
attach
replic
invas
gut
lumen
need
provid
neonat
immun
enter
pathogen
prompt
studi
matern
vaccin
enhanc
passiv
lactogen
immun
matern
antibodi
colostrum
milk
notion
live
oral
vaccin
could
mimic
natur
rout
infect
prefer
convent
inactiv
parenter
vaccin
stimul
protect
lactogen
immun
saif
et
al
put
forth
year
ago
studi
show
tgevseroneg
sow
oral
immun
virul
tgev
induc
high
rate
protect
suckl
neonat
oral
immun
live
tgev
induc
high
titer
siga
antibodi
colostrum
milk
wherea
system
immun
induc
mainli
igg
antibodi
abil
sow
transmit
high
degre
passiv
lactogen
immun
suckl
progeni
close
associ
siga
igg
tgev
antibodi
bohl
saif
first
elabor
concept
gutmammari
glandsiga
immunolog
axi
pioneer
studi
form
part
basic
tenet
common
mucos
immun
system
oral
immun
pregnant
sow
attenu
tgev
rotaviru
vaccin
still
use
induc
passiv
immun
tabl
howev
subsequ
shown
seroposit
natur
infect
pregnant
swine
cattl
lactogen
antibodi
siga
swine
cattl
could
also
enhanc
parenter
vaccin
live
appropri
kill
subunit
vaccin
review
saif
wesley
saif
fernandez
observ
concern
vaccin
effect
tgevseroneg
versu
seroposit
anim
explain
vaccin
inconsist
seen
field
studi
kill
modifi
live
vaccin
administ
oral
parenter
mother
use
extens
increas
lactogen
immun
livestock
discuss
passiv
immun
section
rotaviru
major
caus
dehydr
diarrhea
young
livestock
infant
poultri
saif
fernandez
multipl
rotaviru
serogroup
b
c
e
base
upon
common
innercapsid
antigen
multipl
g
glycoprotein
p
proteasesensit
serotyp
base
neutral
epitop
capsid
protein
group
rotavirus
detect
human
sheep
swine
cattl
hors
poultri
kapikian
et
al
characterist
rotavirus
applic
human
anim
rotavirus
review
chapter
viral
gastroenter
vaccin
among
distinct
rotaviru
serogroup
serotyp
crossprotect
minim
nonexist
antigen
diverg
among
differ
serogenotyp
rotavirus
enter
calicivirus
present
challeng
design
vaccin
capabl
induc
heterotyp
protect
commerci
modifi
live
kill
rotaviru
vaccin
rotaviru
diarrhea
livestock
poultri
limit
group
rotavirus
group
c
rotaviru
pig
saif
fernandez
first
oral
rotaviru
vaccin
calv
develop
year
prior
discoveri
human
rotaviru
use
cellcultureadapt
neonat
calf
diarrhea
rotaviru
ncdv
strain
mebu
et
al
although
signific
reduct
morbid
mortal
observ
field
trial
among
vaccin
calv
major
herd
comparison
previou
year
subsequ
field
studi
reveal
variabl
efficaci
experiment
studi
suggest
matern
antibodi
interf
live
vaccin
replic
suppress
develop
activ
immun
saif
fernandez
neonat
gnotobiot
pig
model
rotaviru
infect
diseas
use
studi
correl
activ
protect
immun
evalu
approach
improv
immunogen
protect
efficaci
rotaviru
vaccin
nearli
decad
saif
et
al
yuan
saif
gnotobiot
pig
free
matern
antibodi
placent
transfer
ig
occur
swine
immunocompet
birth
maintain
asept
free
exposur
extran
rotavirus
ensur
exposur
singl
pathogen
analyz
initi
studi
conduct
mimic
natur
rotaviru
infect
bohl
et
al
examin
immun
correl
protect
saif
et
al
gnotobiot
pig
oral
inocul
virul
attenu
porcin
rotavirus
human
rotaviru
hrv
complet
protect
homotyp
heterotyp
distinct
p
g
type
rotaviru
challeng
hoshino
et
al
saif
et
al
pig
inocul
virul
hrv
develop
significantli
higher
number
virusspecif
iga
igg
antibodyform
cell
afc
memori
b
cell
higher
lymphocyt
prolif
respons
intestin
lamina
propria
pig
inocul
attenu
hrv
ward
et
al
yuan
et
al
pig
inocul
two
three
dose
attenu
hrv
moder
protect
viru
shed
diarrhea
homotyp
challeng
similar
result
clinic
trial
oral
attenu
rotaviru
vaccin
infant
brese
et
al
magnitud
intestin
iga
afc
lymphocyt
prolif
respons
correl
level
protect
induc
ward
et
al
yuan
et
al
immunogen
protect
efficaci
variou
rotaviru
vaccin
formul
attenu
replic
viru
inactiv
viru
recombin
baculovirusexpress
viruslik
particl
vlp
administr
rout
adjuv
also
evalu
gnotobiot
pig
model
saif
et
al
yuan
saif
inactiv
oral
intramuscular
hrv
vaccin
fail
protect
virul
hrv
challeng
despit
high
igg
antibodi
respons
induc
serum
system
lymphoid
tissu
intramuscular
vaccin
rotaviru
subunit
vaccin
consist
doublelay
vlp
compos
rotaviru
inner
capsid
protein
administ
nasal
oral
mutant
heatlabil
toxin
e
coli
mlt
iscom
adjuv
iosef
et
al
yuan
saif
induc
igg
afc
respons
system
lymphoid
tissu
low
iga
afc
respons
intestin
lymphoid
tissu
also
fail
mediat
protect
failur
intramuscularli
administ
inactiv
hrv
vaccin
demonstr
protect
immun
rotaviru
requir
induct
iga
antibodi
intestin
sinc
system
igg
antibodi
alon
effect
failur
nasal
oral
vaccin
suggest
protect
immun
rotaviru
diarrhea
neonat
pig
requir
presenc
intestin
iga
neutral
antibodi
outer
capsid
rotaviru
protein
howev
adjuv
mlt
iscom
use
nasal
oral
booster
dose
pig
oral
prime
attenu
hrv
protect
efficaci
increas
significantli
highest
number
intestin
iga
afc
serum
intestin
iga
antibodi
titer
induc
sequenti
primeboost
regimen
among
vaccin
test
gnotobiot
pig
model
iosef
et
al
yuan
saif
interest
find
prime
two
dose
follow
live
attenu
hrv
ineffect
induc
iga
antibodi
protect
thu
use
replic
vaccin
prime
lymphocyt
major
induct
site
gutassoci
lymphoreticular
tissu
galt
follow
boost
nonrepl
vaccin
second
mucos
induct
site
nasopharyngealassoci
lymphoreticular
tissu
nalt
highli
effect
approach
stimul
mucos
immun
system
induc
activ
protect
immun
infect
diarrhea
use
tgev
model
evalu
activ
protect
diarrhea
pig
research
also
reveal
new
inform
compartment
common
mucos
immun
system
impact
mucos
vaccin
strategi
protect
vancott
et
al
vancott
et
al
natur
occurr
delet
mutant
tgev
exclus
respiratori
tropism
refer
porcin
respiratori
coronaviru
prcv
provid
uniqu
opportun
studi
afc
respons
protect
immun
two
antigen
relat
porcin
coronavirus
enter
tgev
versu
respiratori
prcv
tropism
investig
show
oral
immun
pig
tgev
induc
high
number
iga
afc
intestin
provid
complet
protect
tgev
challeng
wherea
nasal
immun
pig
prcv
induc
mainli
system
immun
respons
igg
afc
provid
partial
protect
tgev
challeng
thu
nasal
prcv
alon
fail
elicit
suffici
intestin
iga
afc
provid
full
protect
enter
pathogen
tgev
find
studi
addit
studi
rotaviru
vaccin
suggest
use
multipl
mucos
induct
site
primeboost
vaccin
regimen
may
effect
approach
overcom
compartment
common
mucos
immun
system
canin
parvoviru
cpv
infect
crypt
enterocyt
caus
hemorrhag
gastroenter
pup
bridger
sinc
cpv
like
dissemin
basolater
surfac
crypt
hematogen
rout
serum
neutral
antibodi
deriv
matern
activ
produc
protect
diseas
demonstr
pup
hemagglutin
inhibit
hi
serum
antibodi
titer
immun
oronas
cpv
type
challeng
pollock
carmichael
cpv
highli
stabl
environ
pup
becam
suscept
infect
soon
matern
antibodi
declin
hi
titer
matern
hi
antibodi
titer
low
sever
affect
efficaci
live
cpv
vaccin
howev
carmichael
et
al
other
compar
immunogen
protect
efficaci
commerci
vaccin
conclud
substanti
differ
exist
abil
immun
protect
pup
matern
antibodi
larson
schultz
past
decad
cpv
vaccin
develop
modifi
live
virus
prove
superior
inactiv
intramuscular
vaccin
appel
studi
pratelli
et
al
show
modifiedl
variant
vaccin
elicit
protect
immun
pup
whose
matern
antibodi
titer
even
pup
antibodi
titer
synthet
peptid
casal
et
al
dna
plasmid
express
jiang
et
al
recombin
vlp
form
baculovirusexpress
casal
chimer
plant
virus
express
peptid
langeveld
et
al
evalu
dog
mice
without
matern
antibodi
demonstr
good
immunogen
andor
protect
efficaci
efficaci
test
pup
presenc
matern
antibodi
need
assess
commerci
potenti
oral
vaccin
induct
activ
immun
bacteri
diarrhea
commonli
use
livestock
although
e
coli
diarrhea
import
problem
postwean
pig
fimbrial
vaccin
routin
administ
parenter
pregnant
cattl
sheep
swine
protect
suckl
neonat
enterotoxigen
e
coli
etec
infect
moon
bunn
vaccin
practic
effect
fimbria
requir
adhesioncolon
bacteria
earli
pathogenesi
diseas
fatal
etec
infect
farm
anim
occur
neonat
period
etec
strain
farm
anim
belong
small
famili
fimbrial
antigen
type
moreov
vaccin
strategi
use
induc
lactogen
immun
parenter
vaccin
fieldexpos
seroposit
mother
shown
effect
parenter
applic
rotaviru
vaccin
rotavirusseroposit
mother
saif
fernandez
saif
jackwood
studi
live
oral
enter
vaccin
anim
clarifi
mechan
induct
protect
immun
enter
diseas
contribut
understand
common
mucos
immun
system
howev
commerci
live
oral
vaccin
often
shown
inadequ
inconsist
efficaci
field
condit
saif
jackwood
major
obstacl
improv
efficaci
oral
vaccin
includ
matern
antibodi
intestin
neonat
mainli
colostrum
milk
antibodi
interfer
live
vaccin
replic
inabl
attenu
vaccin
strain
adequ
infect
stimul
siga
antibodi
intestin
ie
less
immunogen
virul
field
strain
use
inappropri
unstabl
antigen
subunit
vaccin
lack
oral
deliveri
vehicl
mucos
adjuv
subunit
vaccin
infect
pathogen
prior
vaccin
studi
adult
mice
rabbit
shown
inactiv
rotaviru
vaccin
variou
formul
vlp
administ
via
intramuscular
oral
nasal
rout
without
adjuv
induc
complet
signific
partial
protect
rotaviru
infect
crawford
et
al
oneal
et
al
siadatpajouh
cai
howev
protect
infect
diarrhea
assess
adult
mous
rabbit
model
speci
suscept
rotavirusinduc
diarrhea
first
week
life
ciarlet
et
al
ward
et
al
studi
pig
indic
protect
rate
rotaviru
diarrhea
upon
challeng
correl
magnitud
iga
afc
memori
b
cell
respons
intestin
lymphoid
tissu
respons
system
lymphoid
tissu
thu
capac
induc
suffici
level
intestin
iga
afc
antibodi
suffici
memori
b
cell
respons
appear
critic
efficaci
rotaviru
vaccin
larg
anim
like
human
infant
coulson
et
al
rel
import
b
cell
versu
cell
protect
immun
rotaviru
extens
studi
adult
mice
inbr
mous
strain
antibodi
cell
gene
knockout
mice
avail
facilit
studi
franco
greenberg
mcneal
et
al
studi
neither
cell
antibodi
essenti
induct
protect
immun
rotaviru
infect
adult
mice
usual
one
effector
b
cell
necessari
elimin
primari
rotaviru
infect
redund
natur
immun
respons
rotaviru
mice
multipl
immunolog
possibl
nonimmunolog
pathway
resolv
rotaviru
infect
franco
greenberg
age
factor
adult
model
host
differ
pathogenesi
rotaviru
infect
mice
pig
conner
ramig
saif
et
al
use
highli
inbr
mous
strain
contribut
discrep
seen
adult
mous
neonat
gnotobiot
pig
model
develop
effect
vaccin
enter
pathogen
improv
method
need
induc
high
level
intestin
iga
antibodi
appropri
microbi
antigen
vaccin
also
induc
heterotyp
protect
activ
immun
presenc
matern
antibodi
possibl
longlast
immunolog
memori
enter
pathogen
natur
memori
presum
maintain
frequent
boost
repeat
environment
exposur
common
stabl
enter
pathogen
endem
anim
human
popul
novel
vaccin
eg
transgen
plant
adjuv
eg
mlt
iscom
vaccin
deliveri
system
eg
recombin
plant
anim
virus
bacteri
vector
microparticl
explor
evalu
relev
anim
model
recent
studi
show
intramuscular
immun
e
coli
fimbria
reduc
e
coli
excret
fece
suckl
pig
upon
challeng
addit
oh
modul
adjuv
reduc
shed
significantli
associ
secondari
iga
antibodi
respons
postchalleng
addit
cpg
modul
adjuv
reduc
diarrhea
associ
enhanc
lymphocyt
prolif
respons
van
der
stede
et
al
newli
develop
coronaviru
express
system
alonso
et
al
enjuan
et
al
potenti
use
viru
vector
deliveri
mucos
vaccin
sinc
coronavirus
infect
mucos
surfac
respiratori
intestin
tract
vaccin
target
mucos
induct
site
nonpathogen
coronavirus
infect
mani
speci
interest
avail
develop
express
systemsth
tissu
speci
tropism
coronavirus
may
manipul
engin
gene
tropism
determin
target
specif
tissu
individu
host
enjuan
et
al
attenu
typhimurium
strain
express
heterolog
antigen
wide
evalu
mostli
mice
vector
vaccin
human
mucos
pathogen
review
fook
recombin
typhimurium
use
antigen
deliveri
system
oral
immun
chick
coccidian
parasit
eimeria
tenella
pogonka
et
al
recombin
salmonella
vaccin
also
use
express
antigen
tgev
bovin
enterotoxigen
e
coli
etec
fimbria
chen
schifferli
ascon
et
al
transgen
plant
express
recombin
protein
enteropathogen
may
provid
inexpens
edibl
vaccin
induct
intestin
immun
plant
express
antigen
enter
virus
tgev
protein
tuboli
et
al
rotaviru
toxin
b
subunit
fusion
protein
yu
langridg
induc
antibodi
respons
follow
parenter
immun
research
necessari
improv
immun
respons
immunolog
memori
follow
ingest
transgen
plant
vaccin
passiv
transfer
matern
immun
provid
essenti
protect
newborn
mammal
although
neonat
immun
system
compet
mount
primari
immun
respons
antigen
mani
infecti
agent
develop
humor
cellmedi
immun
mani
case
primari
activ
immun
respons
develop
quickli
enough
prevent
diseas
death
matern
immunolog
assist
thu
provid
critic
though
temporari
aid
surviv
neonat
enhanc
passiv
immun
vaccin
mother
success
diseas
prevent
strategi
domest
anim
vaccin
mother
develop
higher
level
specif
antibodi
colostrum
milk
therebi
increas
level
immun
offspr
glezen
saif
fernandez
tizard
passiv
immun
also
enhanc
oral
administr
immun
milk
heterolog
antibodi
prepar
eg
chicken
egg
yolk
igi
ikemori
kuroki
monoclon
antibodi
parenter
administr
hyperimmun
plasma
becu
et
al
unfortun
passiv
antibodi
often
interfer
activ
immun
young
anim
birdsvari
vaccin
strategi
develop
minim
suppress
effect
matern
antibodi
improv
adjuv
antigen
deliveri
system
need
facilit
effici
predict
induct
activ
immun
presenc
matern
antibodiesthi
section
address
past
current
futur
approach
consider
use
passiv
immun
veterinari
speci
transfer
system
passiv
immun
mother
offspr
occur
prenat
via
placenta
yolk
sac
postnat
via
ingest
colostrum
milk
depend
upon
speci
main
ig
isotyp
transfer
speci
igg
mechan
transport
ig
dam
offspr
describ
elsewher
volum
mice
rat
transplacent
transfer
ig
occur
combin
prolong
day
respect
postnat
transfer
mean
colostrum
milk
pastoret
dog
cat
transfer
igg
occur
combin
prenat
postnat
mechan
total
transfer
occur
birth
tizard
rumin
hors
pig
offspr
born
virtual
agammaglobulinem
transmiss
ig
occur
via
colostrum
limit
time
birth
pastoret
wagstrom
et
al
transit
product
colostrum
milk
ig
longer
absorb
intestin
act
local
immunoglobulin
absorpt
neonat
larg
domest
speci
facilit
presenc
proteas
inhibitor
colostrum
westrom
et
al
effici
declin
rapidli
birth
maxim
absorpt
occur
first
hour
cessat
absorpt
intact
macromolecul
term
gut
closur
occur
differ
age
differ
speci
calv
pig
closur
normal
occur
hour
birth
absorpt
colostr
ig
highli
effect
suppli
newborn
serum
antibodi
similar
level
mother
circul
failur
passiv
transfer
common
problem
howev
newborn
calv
foal
besser
gay
tylermcgowan
hodgson
failur
passiv
transfer
may
occur
product
low
quantiti
colostrum
product
colostrum
inadequ
level
matern
antibodi
eg
mastiti
agalactia
ingest
low
quantiti
colostrum
ineffici
absorpt
gut
quigley
drewri
colostr
supplement
replac
arthington
et
al
quigley
drewri
well
plasma
product
develop
commerci
address
problem
variabl
success
sinc
transfer
matern
antibodi
farm
anim
depend
upon
ingest
colostrum
benefit
vaccin
dam
enhanc
passiv
immun
lost
absorpt
colostr
ig
ineffici
hodgin
shewen
halflif
ig
vari
consider
among
speci
domest
anim
recent
find
suggest
fcrn
involv
homeostasi
serum
level
igg
gener
preclud
distinct
mechan
function
neonat
studi
conduct
besser
et
al
besser
et
al
indic
main
rout
clearanc
passiv
acquir
calv
transfer
serum
intestin
approxim
passiv
acquir
elimin
rout
titer
passiv
circul
antibodi
high
enough
transfer
antibodi
circul
intestin
lumen
suffici
effici
mediat
least
shortterm
partial
protect
rotaviru
diarrhea
besser
et
al
mechan
may
function
piglet
review
saif
wesley
et
al
ward
et
al
persist
titer
circul
matern
antibodi
gener
consid
design
vaccin
strategi
young
anim
suppress
effect
matern
antibodi
activ
immun
respons
howev
alway
necessari
wait
titer
matern
antibodi
declin
limit
detect
vaccin
hodgin
shewen
matern
immun
piglet
induct
memori
occur
even
presenc
detect
antibodi
boersema
et
al
experi
colostrumdepriv
lamb
jone
et
al
calv
mosier
et
al
demonstr
abil
parenter
administ
immun
antisera
appropri
specif
high
titer
mediat
protect
follow
experiment
challeng
haemolytica
although
antisera
prepar
haemolytica
continu
market
countri
prevent
pneumonia
calv
lack
document
specif
antibodi
titer
product
make
valu
question
parenter
administr
hyperimmun
plasma
rais
r
equi
shown
protect
pneumonia
young
foal
experiment
hoopermcgrevi
et
al
field
studi
becu
et
al
hyperimmun
plasma
avail
commerci
prophylact
use
foal
prepartum
vaccin
beef
cow
van
donkersgo
et
al
dairi
cow
hodgin
shewen
hodgin
shewen
demonstr
increas
titer
antibodi
haemolytica
colostrum
serum
calv
virtual
adult
cattl
serum
antibodi
haemolytica
vaccin
therefor
serv
trigger
anamnest
respons
rodent
popular
model
studi
passiv
protect
milk
antibodi
howev
rat
mice
activ
transport
igg
gut
circul
first
week
life
thu
antibodi
ingest
milk
contribut
local
system
immun
rodent
contrast
strictli
local
effect
occur
human
domest
anim
pig
hors
dog
cat
igg
abund
ig
colostrum
iga
predomin
milk
parenter
vaccin
enhanc
serum
igg
antibodi
titer
contribut
igg
antibodi
colostrum
limit
effect
iga
antibodi
milk
although
saif
bohl
salmon
observ
iga
antibodi
respons
sow
milk
administr
live
virus
mammari
gland
usual
mechan
induct
iga
antibodi
enter
pathogen
milk
seroneg
anim
rather
swine
bohl
saif
bohl
et
al
saif
et
al
show
iga
antibodi
milk
specif
enter
pathogen
appear
suffici
antigen
stimul
tgev
infect
intestin
basi
observ
first
propos
traffick
iga
lymphoblast
gut
mammari
gland
monogastr
propos
gutmammarysiga
immunolog
axi
provid
part
initi
basi
concept
common
mucos
immun
systemth
traffick
gutorigin
iga
lymphoblast
mammari
gland
confirm
experiment
mice
roux
et
al
subsequ
verifi
swine
salmon
et
al
contrast
sheldrak
husband
found
littl
evid
gutmammari
gland
axi
rumin
instead
rumin
main
isotyp
colostrum
milk
butler
select
transport
serum
primarili
prepartum
also
postpartum
mark
decreas
serum
prepartum
butler
fc
receptor
probabl
fcrn
kacskov
et
al
express
basolater
surfac
mammari
gland
alveolar
epitheli
cell
respons
transport
interest
express
receptor
rumin
traffick
iga
lymphoblast
mammari
gland
monogastr
regul
pregnanc
hormon
prolactin
estrogen
progesteron
weiszcarrington
et
al
barrington
et
al
milk
antibodi
provid
passiv
protect
neonat
intestin
tract
immun
exclus
prevent
attach
virus
bacteria
parasit
neutral
enterotoxin
virul
factor
virus
siga
antibodi
presum
resist
cleavag
digest
enzym
higher
level
milk
appear
effici
mediat
protect
gut
pig
monogastr
saif
jackwood
saif
fernandez
high
persist
level
passiv
igg
antibodi
also
protect
review
saif
wesley
ward
et
al
et
al
rumin
antibodi
also
rel
resist
proteolyt
enzym
brock
et
al
predomin
milk
may
supplant
role
siga
numer
vaccin
market
vaccin
cow
sow
provid
lactogen
immun
rotaviru
coronaviru
e
coli
suckl
offspr
tabl
vaccin
efficaci
variabl
influenc
numer
factor
relat
host
vaccin
manag
discuss
key
concept
follow
coronaviru
rotaviru
enter
vaccin
swine
cattl
serv
exampl
review
saif
jackwood
saif
fernandez
saif
wesley
ideal
suckl
anim
becom
subclin
infect
enter
pathogen
receiv
adequ
passiv
antibodi
prevent
diseas
develop
activ
immun
prime
boersema
et
al
prevent
subsequ
diarrheathi
balanc
passiv
immun
diseas
disrupt
intens
anim
product
system
expos
anim
high
pathogen
dose
confin
contamin
environ
addit
earlier
wean
practic
feed
supplement
milk
replac
curtail
dilut
milk
antibodi
consequ
without
matern
vaccin
antibodi
titer
enter
pathogen
usual
decreas
unprotect
level
milk
matern
enter
vaccin
commonli
use
two
popul
pregnant
anim
control
epidem
infect
epidem
tgev
target
use
seroneg
anim
induc
primari
immun
responsesto
control
endem
infect
rotaviru
e
coli
booster
vaccin
use
seroposit
fieldexpos
anim
stimul
anamnest
respons
vaccin
strategi
latter
vaccin
gener
success
former
reflect
greater
success
design
vaccin
boost
rather
prime
mucos
immun
provid
lactogen
immun
enter
pathogen
date
virul
tgev
given
pregnant
sow
effect
stimul
high
level
iga
antibodi
milk
passiv
protect
review
saif
jackwood
saif
wesley
use
oral
highli
attenu
tgev
vaccin
safe
piglet
replic
poorli
sow
induc
lower
iga
milk
antibodi
titer
low
variabl
efficaci
field
moxley
olsen
parenter
kill
tgev
vaccin
induc
low
milk
igg
antibodi
titer
usual
lowest
protect
rate
attempt
develop
matern
tgev
recombin
subunit
vaccin
base
surfac
tgev
spike
protein
induc
neutral
antibodi
live
vector
vaccin
express
protein
also
limit
success
tgevseroneg
swine
review
saif
wesley
howev
primeboost
strategi
intramuscular
administr
tgev
protein
follow
oralnas
prime
attenu
tgev
shown
promis
mean
enhanc
milk
iga
antibodi
titer
park
et
al
epidem
tgev
outbreak
also
declin
follow
appear
respiratori
variant
tgev
variant
induc
tgevneutr
antibodi
milk
least
moder
protect
tgev
repeat
respiratori
infect
sow
rais
unresolv
question
bronchusassoci
lymphoid
tissu
balt
mammari
gland
lymphocyt
traffick
review
saif
wesley
wherea
tgev
associ
epidem
endem
infect
swine
rotaviru
e
coli
infect
endem
swine
cattl
booster
vaccin
strategi
requir
enhanc
lactogen
immun
endem
enter
pathogen
antibodi
titer
milk
declin
dramat
lactat
although
studi
limit
parenter
vaccin
tgevor
rotavirusseroposit
fieldexpos
pregnant
sow
attenu
vaccin
effect
boost
siga
igg
antibodi
milk
saif
jackwood
saif
fernandez
saif
wesley
find
concur
report
increas
breast
milk
iga
antibodi
women
endem
expos
cholera
parenter
boost
cholera
vaccin
svennerholm
et
al
find
parenter
boost
effect
increas
iga
antibodi
mucos
secret
anim
oral
prime
live
pathogen
consist
observ
intestin
replic
rotaviru
pig
iga
memori
b
cell
initi
resid
ileal
peyer
patch
subsequ
also
present
substanti
number
spleen
bone
marrow
yuan
et
al
thu
system
stimul
iga
memori
b
cell
parenter
booster
vaccin
could
yield
iga
antibodi
serum
transport
mucos
secret
via
polymer
ig
receptor
observ
led
mucos
primeboost
strategi
human
anim
rotaviru
vaccin
current
test
gnotobiot
pig
field
condit
antibodi
endem
intestin
pathogen
also
common
bovin
colostrum
milk
without
boost
effect
highli
immunogen
vaccin
antibodi
titer
often
low
protect
calv
besser
gay
saif
fernandez
saif
jackwood
thu
vaccin
market
prepartum
vaccin
cow
rotaviru
coronaviru
e
coli
enhanc
passiv
immun
calv
tabl
field
efficaci
viral
vaccin
question
waltnertoew
et
al
number
import
variabl
may
account
vaccin
failur
includ
vaccin
titer
dose
inactiv
agent
viru
strain
adjuv
inocul
rout
pariti
mother
review
saif
fernandez
colostrum
milk
rumin
contain
mainli
serumderiv
parenter
intramuscular
subcutan
intramammari
inocul
rotaviru
seroposit
cow
optim
live
inactiv
subunit
vp
vlp
rotaviru
vaccin
effect
boost
virusneutr
antibodi
titer
serum
milk
posit
correl
shown
serum
titer
rotavirusneutr
antibodi
neonat
beef
calv
resist
rotaviru
diarrhea
kohara
tsunemitsu
vaccin
pregnant
dairi
cow
modifi
live
plaqueform
unit
binari
ethyleneamin
inactiv
rotaviru
incomplet
freund
adjuv
ifa
aloh
adjuv
recombin
vlp
ifa
significantli
increas
titer
virusneutr
antibodi
rotaviru
colostrum
milk
saif
fernandez
kim
et
al
colostr
supplement
mediat
passiv
protect
calv
experiment
oral
rotaviru
challeng
review
saif
fernandez
prepartum
vaccin
cow
sow
bacterin
prepar
enteropathogen
e
coli
prevent
diarrhea
offspr
also
commonli
practic
tabl
modern
farm
practic
dairi
veal
calv
rare
fed
whole
milk
dam
day
thu
vaccin
efficaci
base
antibodi
absorb
colostrum
retain
temporarili
gut
rather
continu
suppli
immun
milk
besser
et
al
demonstr
transfer
passiv
antibodi
serum
intestin
calv
could
mediat
shortterm
protect
piglet
contrast
continu
receiv
immun
milk
wean
week
age
import
continu
suppli
passiv
antibodi
protect
tgev
demonstr
experiment
saif
wesley
numer
commerci
ig
prepar
antibodi
activ
specif
enter
pathogen
market
past
sever
decad
product
intend
prevent
e
coli
enter
calv
includ
dri
bovin
colostrum
whey
hyperimmun
sera
rais
hors
mous
monoclon
antibodi
antigen
e
coli
product
administ
oral
first
hour
life
prevent
adhes
enteropathogen
e
coli
bovin
ig
product
contain
antibodi
antigen
e
coli
pathogen
neonat
pig
also
market
oral
use
piglet
oral
administ
bovin
colostr
whey
contain
rotaviru
antibodi
also
passiv
protect
piglet
absenc
circul
antibodi
rotaviru
dosedepend
manner
interfer
induct
activ
serum
antibodi
respons
schaller
et
al
immun
chicken
show
promis
effici
method
produc
polyclon
antibodi
passiv
protect
specif
antibodi
igi
isotyp
induc
vaccin
concentr
egg
yolk
lay
hen
produc
g
igi
per
yearyolk
antibodi
viru
neutral
activ
provid
partial
protect
rotaviru
kuroki
et
al
coronaviru
diarrhea
yolk
antibodi
also
provid
protect
enterotoxigen
e
coli
calv
ikemori
et
al
piglet
yokoyama
et
al
protect
effect
yolk
antibodi
depend
antibodi
titer
oral
prepar
marquardt
thu
develop
better
mean
protect
yolk
antibodi
digest
process
improv
efficaci
econom
viabil
yolk
antibodi
clinic
applic
mine
kovacsnolan
mani
diseas
newborn
neonat
passiv
immun
practic
mean
provid
time
protect
unfortun
well
document
matern
antibodi
suppress
activ
immun
respons
follow
vaccin
effect
observ
live
nonrepl
vaccin
system
mucos
immun
respons
siegrist
et
al
et
al
antibodi
respons
especi
affect
recent
evid
suggest
tlymphocyt
respons
may
suppress
siegrist
et
al
titer
matern
antibodi
maxim
speci
interest
first
week
life
declin
gradual
next
month
variabl
titer
among
individu
high
mani
vaccin
window
diseas
suscept
variabl
durat
occur
titer
matern
antibodi
low
mediat
protect
high
permit
effect
vaccin
number
strategi
use
cope
problem
veterinari
vaccin
cattl
sold
disclaim
anim
vaccin
month
age
receiv
booster
dose
vaccin
month
age
provid
littl
solac
mani
diseas
cattl
occur
first
week
month
life
common
strategi
vaccin
dog
cat
administ
seri
dose
vaccin
earli
age
individu
respons
continu
vaccin
age
virtual
respond
vaccin
strategi
econom
disadvantag
pet
owner
manufactur
produc
lowpassag
highvirustit
vaccin
especi
use
situat
high
titer
matern
antibodi
high
pathogen
exposur
anticip
similar
strategi
longer
approv
world
health
organ
vaccin
children
develop
countri
measl
gellin
katz
preliminari
evid
suggest
incorpor
vaccin
antigen
highli
structur
iscom
nasal
applic
vaccin
enhanc
immun
respons
presenc
matern
antibodi
van
binnendijk
et
al
brockmeier
et
al
matern
vaccin
enhanc
passiv
immun
alreadi
wide
use
veterinari
medicin
vaccin
especi
vaccin
enter
virus
limit
efficaci
new
approach
need
enhanc
immunogen
econom
viabl
manner
commerci
product
alreadi
develop
supplement
newborn
receiv
inadequ
amount
qualiti
colostrum
although
product
contain
guarante
minimum
titer
antibodi
specif
organ
need
expand
qualiti
control
addit
common
pathogen
neonat
urgent
need
develop
adjuv
deliveri
system
capabl
reliabl
induc
activ
immun
neonat
spite
presenc
matern
antibodi
abil
provid
continu
immun
protect
birth
combin
passiv
immun
activ
immun
would
major
impact
neonat
morbid
mortal
anim
human
research
mucos
veterinari
vaccin
contribut
new
concept
field
mucos
immun
investig
pathogenhost
interact
outbr
anim
illustr
complex
interact
encourag
rethink
establish
paradigm
earli
studi
enter
coronaviru
infect
swine
tgev
led
concept
gutmammari
glandsiga
immunolog
axi
provid
part
basic
tenet
common
mucos
immun
system
saif
et
al
later
studi
tgev
delet
mutant
tgev
respiratori
tropism
prcv
reveal
function
compartment
exist
within
common
mucos
immun
system
wherebi
nasal
inocul
pig
prcv
fail
elicit
suffici
intestin
iga
antibodi
respons
fulli
protect
enter
pathogen
tgev
van
cott
et
al
subsequ
studi
explor
new
primeboost
mucos
immun
strategi
elicit
intestin
immun
enter
pathogen
rotaviru
pig
saif
yuan
saif
studi
oral
prime
attenu
viru
led
success
nasal
booster
respons
use
nonrepl
vlp
vaccin
combin
mucos
adjuv
iscom
mltthu
use
replic
vaccin
prime
lymphocyt
major
mucos
induct
site
galt
follow
boost
nonrepl
vaccin
second
induct
site
nalt
effect
stimul
intestin
iga
antibodi
induc
activ
protect
rotaviru
diarrhea
although
progress
develop
safe
effect
nonrepl
vaccin
boost
mucos
immun
respons
includ
use
parenter
booster
vaccin
fieldexpos
anim
saif
fernandez
still
need
develop
effect
safe
vaccin
prime
mucos
immun
mucos
adjuv
mlt
iscom
cpg
cytokin
rankin
et
al
new
deliveri
system
replic
vector
microparticl
bowersock
et
al
shown
promis
anim
studi
review
chapter
howev
econom
product
final
evalu
field
condit
includ
presenc
matern
antibodi
relev
need
consider
research
effort
devot
develop
vaccin
respiratori
diseas
domest
anim
instanc
attenu
organ
deliv
mucos
rout
demonstr
improv
efficaci
nonrepl
antigen
given
system
rout
mani
respiratori
diseas
howev
progress
develop
mucos
vaccin
await
advanc
understand
diseas
pathogenesi
identif
protect
antigen
contrast
studi
ascend
infect
reproduct
tract
cattl
demonstr
efficaci
system
vaccin
clear
establish
infect
highlight
possibl
therapeut
vaccin
final
import
realiz
speci
differ
consid
design
vaccin
elicit
mucos
immun
exampl
primari
ig
mammari
secret
rumin
activ
transport
mammari
gland
serum
provid
effect
passiv
immun
nurs
offspr
enter
pathogen
thu
parenter
immun
mother
effect
stimul
passiv
immun
rumin
enter
pathogen
contrast
monogastr
iga
predomin
milk
iga
lymphoblast
traffic
mammari
gland
origin
intestin
therefor
oral
vaccin
monogastr
may
provid
effect
vaccin
strategi
induc
iga
antibodi
milk
enter
pathogen
saif
fernandez
aforement
vaccin
concept
one
review
chapter
appli
new
effect
mucos
adjuv
deliveri
system
bioengin
vector
express
appropri
microbi
antigen
like
new
gener
veterinari
vaccin
emerg
better
cope
exist
emerg
mucos
pathogen
